AZD7789 clinical trials

A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, in Participants with Advanced or Metastatic Solid Tumors

This study is testing a new medicine, AZD7789, for people with advanced cancers like stomach or lung cancer. It's looking to see if the medicine is safe, how it works in the body, and if it can help shrink tumors.